Jean Jacques Bienaime - 28 Apr 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
28 Apr 2022
Net transactions value
-$1,149,050
Form type
4
Filing time
02 May 2022, 21:27:41 UTC
Previous filing
20 Apr 2022
Next filing
09 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $749,200 +20,000 +6% $37.46 354,983 28 Apr 2022 Direct F1
transaction BMRN Common Stock Sale $1,675,800 -20,000 -5.6% $83.79 334,983 28 Apr 2022 Direct F1
transaction BMRN Common Stock Options Exercise $187,300 +5,000 +1.5% $37.46 339,983 29 Apr 2022 Direct F2
transaction BMRN Common Stock Sale $409,750 -5,000 -1.5% $81.95 334,983 29 Apr 2022 Direct F2
holding BMRN Common Stock 247,533 28 Apr 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -20,000 -36% $0.000000 35,000 28 Apr 2022 Common Stock 20,000 $37.46 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5,000 -14% $0.000000 30,000 29 Apr 2022 Common Stock 5,000 $37.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.